At present, there are several Gal3 inhibitors in clinical trials for the treatment of nonalcoholic steatohepatitis (NASH), liver cirrhosis, portal hypertension or tumors36,51,52, indicating that Gal3 is a druggable target. This evidence concerns the gene LGALS3 and metabolic dysfunction-associated steatohepatitis.